3BONNEL RA, BUSSE GD. Zolendronic acid (marketed as reclast) : renal impairment and acute renal failure[ J]. Drug Safety Newsletter, 2009,2(2) : 26-27.
4ROSEN ES, GORDEN D, KAMINSKI M, et al. Long-term efficacy and safely of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myelomaor breast carcinoma: a randomized, double-blind, multicenter, comparative trial[ J]. Cancer, 2003,98 ( 8 ) : 1735 - 1744.
6Rakel A, Boucher A, Ste-Marie LG. Role of zoledronic acid in the prevention and treatment of osteoporosis [ J ]. Clin Interv Aging, 2011, 6 : 89-99.
7Eastell R, Black DM, Boonen S, et al. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density[ J]. J Clin Endocrinal Metab, 2009, 94 (9) :3215-3225.
8Wellington K,Goa KL.Zoledronic acid:a review of its use in the management of bone metastases and hypercalcaemia of malignancy[J].Drugs,2003,63:417-437.
9Reid IR,Brown JP,Burckhardt P,et al.Intravenous zoledronic acid in postmenopausal women with low bone mineral density[J].N Engl J Med,2002,346:653-661.
10Body JJ,Lortholary A,Romieu G,et al.A dose-finding study of zoledronate in hypercalcemic cancer patient[J].J Bone Miner Res,1999,14:1557-1561.
